DEXCOM INC 8-K

What Happened
On May 14, 2026, DexCom, Inc. held its 2026 Investor Day in Mesa, Arizona and posted the investor presentation and webcast replay to its website. At the event, Dexcom announced long-range, 2030 non-GAAP financial targets and the Board approved a new share repurchase program. The new financial targets are: organic revenue growth of 10%+ annually through 2030; 2030 non-GAAP gross profit margin of 67–69%; 2030 non-GAAP operating profit margin of 29–30%; and 2030 adjusted EBITDA margin of 36–37%.

Key Details

• Investor Day date: May 14, 2026; presentation and webcast posted to Dexcom’s investor relations site (web materials not part of the 8-K).
• New long-range targets: 10%+ organic revenue growth annually through 2030; gross margin 67–69%; operating margin 29–30%; adjusted EBITDA margin 36–37% (all non-GAAP).
• Share repurchase program: Board authorized up to $1.0 billion of common stock repurchases, with a repurchase period ending no later than June 30, 2027.
• Prior program terminated: $250.0 million remained available under the previous repurchase program and was cancelled upon approval of the new program. Repurchases may occur in the open market, via private transactions, or through 10b5-1 plans and are at Dexcom’s discretion.

Why It Matters
These announcements give investors forward-looking targets for growth and profitability through 2030 and signal management’s confidence in margin expansion and cash generation. The $1.0B buyback authorization is a direct capital-return action that can reduce shares outstanding and support earnings per share, but repurchases are discretionary and not guaranteed. Investors should note the targets are non-GAAP and forward-looking and are subject to risks and uncertainties described in Dexcom’s SEC filings.